Cargando…

Human Tissue Angiotensin Converting Enzyme (ACE) Activity Is Regulated by Genetic Polymorphisms, Posttranslational Modifications, Endogenous Inhibitors and Secretion in the Serum, Lungs and Heart

Objective: Inhibitors of the angiotensin converting enzyme (ACE) are the primarily chosen drugs to treat heart failure and hypertension. Moreover, an imbalance in tissue ACE/ACE2 activity is implicated in COVID-19. In the present study, we tested the relationships between circulating and tissue (lun...

Descripción completa

Detalles Bibliográficos
Autores principales: Bánhegyi, Viktor, Enyedi, Attila, Fülöp, Gábor Áron, Oláh, Attila, Siket, Ivetta Mányiné, Váradi, Csongor, Bottyán, Klaudia, Lódi, Mária, Csongrádi, Alexandra, Umar, Azeem J., Fagyas, Miklós, Czuriga, Dániel, Édes, István, Pólos, Miklós, Merkely, Béla, Csanádi, Zoltán, Papp, Zoltán, Szabó, Gábor, Radovits, Tamás, Takács, István, Tóth, Attila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305685/
https://www.ncbi.nlm.nih.gov/pubmed/34359878
http://dx.doi.org/10.3390/cells10071708
_version_ 1783727632115826688
author Bánhegyi, Viktor
Enyedi, Attila
Fülöp, Gábor Áron
Oláh, Attila
Siket, Ivetta Mányiné
Váradi, Csongor
Bottyán, Klaudia
Lódi, Mária
Csongrádi, Alexandra
Umar, Azeem J.
Fagyas, Miklós
Czuriga, Dániel
Édes, István
Pólos, Miklós
Merkely, Béla
Csanádi, Zoltán
Papp, Zoltán
Szabó, Gábor
Radovits, Tamás
Takács, István
Tóth, Attila
author_facet Bánhegyi, Viktor
Enyedi, Attila
Fülöp, Gábor Áron
Oláh, Attila
Siket, Ivetta Mányiné
Váradi, Csongor
Bottyán, Klaudia
Lódi, Mária
Csongrádi, Alexandra
Umar, Azeem J.
Fagyas, Miklós
Czuriga, Dániel
Édes, István
Pólos, Miklós
Merkely, Béla
Csanádi, Zoltán
Papp, Zoltán
Szabó, Gábor
Radovits, Tamás
Takács, István
Tóth, Attila
author_sort Bánhegyi, Viktor
collection PubMed
description Objective: Inhibitors of the angiotensin converting enzyme (ACE) are the primarily chosen drugs to treat heart failure and hypertension. Moreover, an imbalance in tissue ACE/ACE2 activity is implicated in COVID-19. In the present study, we tested the relationships between circulating and tissue (lung and heart) ACE levels in men. Methods: Serum, lung (n = 91) and heart (n = 72) tissue samples were collected from Caucasian patients undergoing lung surgery or heart transplantation. ACE I/D genotype, ACE concentration and ACE activity were determined from serum and tissue samples. Clinical parameters were also recorded. Results: A protocol for ACE extraction was developed for tissue ACE measurements. Extraction of tissue-localized ACE was optimal in a 0.3% Triton-X-100 containing buffer, resulting in 260 ± 12% higher ACE activity over detergent-free conditions. SDS or higher Triton-X-100 concentrations inhibited the ACE activity. Serum ACE concentration correlated with ACE I/D genotype (II: 166 ± 143 ng/mL, n = 19, ID: 198 ± 113 ng/mL, n = 44 and DD: 258 ± 109 ng/mL, n = 28, p < 0.05) as expected. In contrast, ACE expression levels in the lung tissue were approximately the same irrespective of the ACE I/D genotype (II: 1423 ± 1276 ng/mg, ID: 1040 ± 712 ng/mg and DD: 930 ± 1273 ng/mg, p > 0.05) in the same patients (values are in median ± IQR). Moreover, no correlations were found between circulating and lung tissue ACE concentrations and activities (Spearman’s p > 0.05). In contrast, a significant correlation was identified between ACE activities in serum and heart tissues (Spearman’s Rho = 0.32, p < 0.01). Finally, ACE activities in lung and the serum were endogenously inhibited to similar degrees (i.e., to 69 ± 1% and 53 ± 2%, respectively). Conclusion: Our data suggest that circulating ACE activity correlates with left ventricular ACE, but not with lung ACE in human. More specifically, ACE activity is tightly coordinated by genotype-dependent expression, endogenous inhibition and secretion mechanisms.
format Online
Article
Text
id pubmed-8305685
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83056852021-07-25 Human Tissue Angiotensin Converting Enzyme (ACE) Activity Is Regulated by Genetic Polymorphisms, Posttranslational Modifications, Endogenous Inhibitors and Secretion in the Serum, Lungs and Heart Bánhegyi, Viktor Enyedi, Attila Fülöp, Gábor Áron Oláh, Attila Siket, Ivetta Mányiné Váradi, Csongor Bottyán, Klaudia Lódi, Mária Csongrádi, Alexandra Umar, Azeem J. Fagyas, Miklós Czuriga, Dániel Édes, István Pólos, Miklós Merkely, Béla Csanádi, Zoltán Papp, Zoltán Szabó, Gábor Radovits, Tamás Takács, István Tóth, Attila Cells Article Objective: Inhibitors of the angiotensin converting enzyme (ACE) are the primarily chosen drugs to treat heart failure and hypertension. Moreover, an imbalance in tissue ACE/ACE2 activity is implicated in COVID-19. In the present study, we tested the relationships between circulating and tissue (lung and heart) ACE levels in men. Methods: Serum, lung (n = 91) and heart (n = 72) tissue samples were collected from Caucasian patients undergoing lung surgery or heart transplantation. ACE I/D genotype, ACE concentration and ACE activity were determined from serum and tissue samples. Clinical parameters were also recorded. Results: A protocol for ACE extraction was developed for tissue ACE measurements. Extraction of tissue-localized ACE was optimal in a 0.3% Triton-X-100 containing buffer, resulting in 260 ± 12% higher ACE activity over detergent-free conditions. SDS or higher Triton-X-100 concentrations inhibited the ACE activity. Serum ACE concentration correlated with ACE I/D genotype (II: 166 ± 143 ng/mL, n = 19, ID: 198 ± 113 ng/mL, n = 44 and DD: 258 ± 109 ng/mL, n = 28, p < 0.05) as expected. In contrast, ACE expression levels in the lung tissue were approximately the same irrespective of the ACE I/D genotype (II: 1423 ± 1276 ng/mg, ID: 1040 ± 712 ng/mg and DD: 930 ± 1273 ng/mg, p > 0.05) in the same patients (values are in median ± IQR). Moreover, no correlations were found between circulating and lung tissue ACE concentrations and activities (Spearman’s p > 0.05). In contrast, a significant correlation was identified between ACE activities in serum and heart tissues (Spearman’s Rho = 0.32, p < 0.01). Finally, ACE activities in lung and the serum were endogenously inhibited to similar degrees (i.e., to 69 ± 1% and 53 ± 2%, respectively). Conclusion: Our data suggest that circulating ACE activity correlates with left ventricular ACE, but not with lung ACE in human. More specifically, ACE activity is tightly coordinated by genotype-dependent expression, endogenous inhibition and secretion mechanisms. MDPI 2021-07-06 /pmc/articles/PMC8305685/ /pubmed/34359878 http://dx.doi.org/10.3390/cells10071708 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bánhegyi, Viktor
Enyedi, Attila
Fülöp, Gábor Áron
Oláh, Attila
Siket, Ivetta Mányiné
Váradi, Csongor
Bottyán, Klaudia
Lódi, Mária
Csongrádi, Alexandra
Umar, Azeem J.
Fagyas, Miklós
Czuriga, Dániel
Édes, István
Pólos, Miklós
Merkely, Béla
Csanádi, Zoltán
Papp, Zoltán
Szabó, Gábor
Radovits, Tamás
Takács, István
Tóth, Attila
Human Tissue Angiotensin Converting Enzyme (ACE) Activity Is Regulated by Genetic Polymorphisms, Posttranslational Modifications, Endogenous Inhibitors and Secretion in the Serum, Lungs and Heart
title Human Tissue Angiotensin Converting Enzyme (ACE) Activity Is Regulated by Genetic Polymorphisms, Posttranslational Modifications, Endogenous Inhibitors and Secretion in the Serum, Lungs and Heart
title_full Human Tissue Angiotensin Converting Enzyme (ACE) Activity Is Regulated by Genetic Polymorphisms, Posttranslational Modifications, Endogenous Inhibitors and Secretion in the Serum, Lungs and Heart
title_fullStr Human Tissue Angiotensin Converting Enzyme (ACE) Activity Is Regulated by Genetic Polymorphisms, Posttranslational Modifications, Endogenous Inhibitors and Secretion in the Serum, Lungs and Heart
title_full_unstemmed Human Tissue Angiotensin Converting Enzyme (ACE) Activity Is Regulated by Genetic Polymorphisms, Posttranslational Modifications, Endogenous Inhibitors and Secretion in the Serum, Lungs and Heart
title_short Human Tissue Angiotensin Converting Enzyme (ACE) Activity Is Regulated by Genetic Polymorphisms, Posttranslational Modifications, Endogenous Inhibitors and Secretion in the Serum, Lungs and Heart
title_sort human tissue angiotensin converting enzyme (ace) activity is regulated by genetic polymorphisms, posttranslational modifications, endogenous inhibitors and secretion in the serum, lungs and heart
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305685/
https://www.ncbi.nlm.nih.gov/pubmed/34359878
http://dx.doi.org/10.3390/cells10071708
work_keys_str_mv AT banhegyiviktor humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT enyediattila humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT fulopgaboraron humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT olahattila humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT siketivettamanyine humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT varadicsongor humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT bottyanklaudia humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT lodimaria humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT csongradialexandra humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT umarazeemj humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT fagyasmiklos humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT czurigadaniel humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT edesistvan humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT polosmiklos humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT merkelybela humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT csanadizoltan humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT pappzoltan humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT szabogabor humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT radovitstamas humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT takacsistvan humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart
AT tothattila humantissueangiotensinconvertingenzymeaceactivityisregulatedbygeneticpolymorphismsposttranslationalmodificationsendogenousinhibitorsandsecretionintheserumlungsandheart